Please assess the completion status of the following clinical trial:

Trial Title: 3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically proven invasive ductal carcinoma of the breast~  * Stage I or II disease (pathological tumor size ≤ 3 cm, N0, M0 disease)~    * No T2 (tumor size \> 3 cm) or T3 disease~   * No lymph node (L0) or hemangiosis (V0) invasion~* Unilateral, unifocal, and unicentric tumor without associated suspicious diffuse microcalcification in the ipsilateral or contralateral breast~  * No multifocal/multicentric disease~* Previously treated with breast-conserving surgery with adequate axillary node management~  * Negative surgical resection margins for tumor (invasive tumor or ductal carcinoma in situ \[DCIS\]) on histology~ * Clearly identified primary tumor excision cavity (clips recommended) with a target lumpectomy cavity/whole breast ratio quantifiable and ≤ 25% on the post-operative CT scan~    * Patients with a lumpectomy cavity/whole breast ratio 25-30% are eligible but will undergo partial breast irradiation using multi-catheter interstitial brachytherapy during study~* Breast size amenable to partial breast irradiation (i.e., \> A-cup size)~* No other pathological invasive tumor or DCIS~* No associated extensive DCIS component (\< 25%)~* No associated Paget's disease of the nipple~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No breast implants~* No collagen vascular disease~* No psychiatric condition or other condition that, in the opinion of the investigator, would preclude study requirements~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior radiotherapy~* No concurrent chemotherapy~  * Sequential chemotherapy allowed~* Concurrent hormonal therapy allowed

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients undergo accelerated partial breast irradiation (APBI) using 3-dimensional conformal radiation therapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: EXPERIMENTAL): Patients undergo APBI using multi-catheter interstitial brachytherapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).